Scaling MRNA Vaccine Technologies: Lessons from Global Deployment for Future Commercialization

Abstract

Moderna and applied mRNA vaccine technology has accelerated the development and deployment of vaccines at a record pace and high effectiveness displayed during the COVID 19 crisis. The relevance, variety, and global experiences of scaling mRNA vaccine technologies within the present and for future commercialization are discussed in this paper. These are manufacturability, supply chain security, supportable regulatory procedures, and sustainability, especially for LMI nations. These targets of mRNA go beyond infectious diseases to encompass cancer immunotherapy, genetic disease, and solutions to antibiotic resistance. Experience from the pandemic highlights the need for cooperation, trust, and changes in storage and delivery techniques. Economic sustainability and affordability always go hand in hand since businesses should aim at making their products key while at the same time being able to make good profits in the market. Pricing is a crucial factor for consumers as it determines the cost of crucial goods and services such as; healthcare, education, or basic services for that matter, even to the humble consumers. To businesses, this dynamic of sustaining the company’s feasibility as it aims at an affordability level is beneficial in the sense that consumers are loyal, the available market is tapped widely and a business will stand the test of time. Therefore, the management of these factors ensures that business sustain their operations while ensuring consumers get an equal chance to access their preferred products. These lessons highlight on the trade-offs and potential solutions, which are the foreseeing abilities, teamwork, and creativity in addressing these odds and actualizing the impacts of mRNA in global health.